Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab

We evaluated the pharmacokinetics, pharmacodynamics, and safety of a single subcutaneous dose of romosozumab 210 mg, a monoclonal antibody against sclerostin, in an open‐label, parallel‐group study in participants with severe (stage 4) renal impairment (RI; n = 8) or end‐stage renal disease requirin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Cheng‐Pang, Maddox, Judy, Block, Geoffrey, Bartley, Yessenia, Yu, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542825/
https://www.ncbi.nlm.nih.gov/pubmed/35304747
http://dx.doi.org/10.1002/jcph.2050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542825/
https://www.ncbi.nlm.nih.gov/pubmed/35304747
http://dx.doi.org/10.1002/jcph.2050

Ejemplares similares